bremelanotide (China)

Bremelanotide is Palatin’s new drug candidate for the treatment of male and female sexual dysfunction First in a new class of therapies called melanocortin agonists, Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available. Bremelanotide works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products. the drug was shown to be safe and well tolerated.